Zinc and new acid reducer tested in h. pylori battle

NCT ID NCT07275827

Not yet recruiting Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial will test how well two different triple therapies—one using a standard acid reducer (proton pump inhibitor) and one using a newer drug (vonoprazan)—work to eliminate H. pylori infection. It will also see if adding zinc improves results. The study plans to enroll 88 adults who test positive for H. pylori and will measure infection clearance and blood markers of inflammation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zinc sulfate, vonoprazan, amoxicillin, clarithromycin, proton pump inhibitor (omeprazole or pantoprazole)
What this could lead to: If successful, this study could show that adding zinc or using vonoprazan instead of a standard acid reducer improves H. pylori cure rates.
What could go wrong: This is a small, early-phase trial (88 people) that has not yet started. Results may not apply to everyone, and some people may have side effects from the antibiotics or zinc.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTIONS

Contacts and locations

Locations

National Liver Institute

Shibīn al Kawm, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.